BIOCON
BIOCON LIMITED.
Each stock's 10,000-path forecast, rendered as light.
BIOCON LIMITED. (BIOCON) Stock Analysis & Case Study
Is BIOCON a good buy? The data-driven verdict.
BIOCON LIMITED. (BIOCON) trades at ₹426,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, BIOCON LIMITED. (BIOCON) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 95.5× earnings, ROE of 1.4%, a 58% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
BIOCON fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How BIOCON ranks against the 2,373 companies in our screener
- BIOCON's market cap of 69,482 Cr ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BIOCON's book value of ₹210 ranks in the 73rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BIOCON's promoter holding of 44.7% ranks in the 22nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BIOCON's 3-year profit (PAT) growth of -15.0% ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BIOCON's 3-year revenue growth of 15.0% ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BIOCON's debt-to-equity ratio of 0.45x is lower than 39% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is BIOCON overvalued? BIOCON P/E vs its Pharma
BIOCON's P/E of 95.5× sits above the Pharma peer median of 33.0×, so on earnings it screens richer than peers, while its 0.12% dividend yield is below the peer median of 0.68%.
BIOCON share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of BIOCON history (11%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| BIOCON 2027 | ₹304 | ₹452 | ₹672 | +6% |
| BIOCON 2028 | ₹274 | ₹479 | ₹837 | +12% |
| BIOCON 2029 | ₹253 | ₹508 | ₹1,021 | +19% |
| BIOCON 2030 | ₹244 | ₹539 | ₹1,187 | +26% |
| BIOCON 2031 | ₹234 | ₹571 | ₹1,395 | +34% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability BIOCON goes up, or doubles?
The bull case for BIOCON
- BIOCON LIMITED. is part of the nifty100 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,021.
The bear case & risks
- BIOCON's P/E of 95.5x is lower than 11% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BIOCON's return on equity of 1.4% ranks in the 17th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹253.
BIOCON volatility & expected range, how bumpy is the ride?
Over the last 9.8 years BIOCON compounded at 11%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹304-₹672, the honest backbone behind any single price target.
BIOCON price forecast, the full 60-month probability fan
BIOCON price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds BIOCON hits common targets within the simulated horizon?
Full multi-horizon detail on the BIOCON price target & forecast page.
BIOCON Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. BIOCON scores 5/8, mixed financial health.
BIOCON MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy BIOCON with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 25.49% | 3.9× |
| Zerodha | 24.70% | 4.0× |
| Groww | 24.71% | 4.0× |
| Dhan | 24.00% | 4.2× |
| Kotak NeoCHEAPEST | 22.03% | 4.5× |
| Paytm Money | 22.36% | 4.5× |
| Pocketful | 29.32% | 3.4× |
| Anand Rathi | 29.01% | 3.4× |
| Bajaj Broking | 24.00% | 4.2× |
| Share India | 29.00% | 3.4× |
Compare every broker on the BIOCON MTF page.
BIOCON vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| BIOCON (this stock) | 95.5× | 0.12% | ₹69,482 Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About BIOCON LIMITED.: sector, index & market-cap context
BIOCON LIMITED. (BIOCON) is a mid-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 500 index, with a market capitalisation of ₹69,482 Cr. See more stocks on our screener.
How the BIOCON Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of BIOCON LIMITED.'s public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
BIOCON analysis, FAQs
Is BIOCON LIMITED. (BIOCON) a good buy?
On the numbers, BIOCON LIMITED. (BIOCON) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 95.5× earnings, ROE of 1.4%, a 58% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is BIOCON overvalued or undervalued?
BIOCON trades at 95.5× earnings versus a peer median of 33.0×, so it screens richer than its Pharma peers.
What is the BIOCON share price target for 2031?
BIOCON's probability-weighted 2031 median target is ₹571, with an 80% range of ₹234-₹1,395 (10,000-path Monte-Carlo).
What is the probability BIOCON doubles in 5 years?
The modelled probability of BIOCON reaching ₹853 (2×) within 5 years is 28%.
What is the bull case for BIOCON?
BIOCON LIMITED. is part of the nifty100 universe with live, tracked fundamentals on Downstox.
What are the risks in BIOCON?
BIOCON's P/E of 95.5x is lower than 11% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. BIOCON's return on equity of 1.4% ranks in the 17th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.